DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Kirsten Gruis - Chief Medical Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alex Nowak - Craig-Hallum Capital Group Elemer Piros - ROTH Capital Partners Francois Brisebois - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Ther ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission File Number: 001-36291 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Br ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Kirsten Gruis - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Capital Group Francois Brisebois - Oppenheimer & Co. Inc. Elemer Piros - ROTH Capital Partners Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2022 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2021 Earnings Conference Call March 15, 2022 8:00 AM ET Company Participants Rick Pauls - President & Chief Executive Officer Kirsten Gruis - Chief Medical Officer Dominic Cundari - Chief Commercial Officer Scott Kellen - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Fourth Quarter 2021 Conference Call. An audio recording of the we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission file number: 001-36291 ____________________ DIAMEDICA THERAPEUTICS INC. (Exact na ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2021 Earnings Conference Call November 11, 2021 8:00 AM ET Company Participants Rick Pauls - President, CEO & Director Scott Kellen - CFO & Company Secretary Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Thomas Flaten - Lake Street Capital Markets Francois Brisebois - Oppenheimer Operator Good morning, ladies and gentlemen and welcome to the DiaMedica Therapeutics Third Quarter 2021 Conference Call. An audio recording of the webcast will be ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from ________________ to __________________. Commission File Number: 001-36291 ____________________ DIAMEDICA THERAPEUTICS INC ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2021 Earnings Conference Call August 12, 2021 8:00 AM ET Company Participants Rick Pauls - President, CEO & Director Scott Kellen - CFO & Company Secretary Conference Call Participants Etzer Darout - Guggenheim Securities Alex Nowak - Craig-Hallum Capital Thomas Flaten - Lake Street Capital Francois Brisebois - Oppenheimer Operator Good morning, ladies and gentlemen. And welcome to the DiaMedica Therapeutics Second Quarter 2021 Conference Call. An audio recording ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from __ ...